PathMaker Neurosystems develops non-invasive neuromodulation devices that utilize multi-site direct current stimulation to normalize neuronal hyperexcitability and reduce protein aggregation in motor neurons. The company focuses on treating ALS and other serious neurological disorders by restoring damaged neural pathways, aiming to make ALS a more manageable condition.
Funding
$2.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Amyotrophic Lateral Sclerosis (ALS) and other neurological disorders damage neural pathways, leading to neuronal hyperexcitability and protein aggregation in motor neurons. Current treatments offer limited efficacy in restoring these damaged pathways and managing the progression of these debilitating conditions.
Solution
PathMaker Neurosystems is developing non-invasive neuromodulation devices utilizing multi-site direct current stimulation (Multi-Site DCS) to address neuronal hyperexcitability and protein aggregation. Their proprietary technology aims to restore damaged neural pathways by normalizing pathway overactivity and reducing protein aggregation in motor neurons. This approach offers a novel treatment paradigm for ALS and other serious neurological disorders, with the goal of making ALS a more manageable condition.
Target Audience
The primary target audience includes individuals diagnosed with ALS and other serious neurological disorders, as well as clinicians and researchers specializing in these conditions.
Features
- Multi-site direct current stimulation (Multi-Site DCS) technology for non-invasive neuromodulation.
- Targeted suppression of neuronal hyperexcitability.
- Activation of neuronal protein degradation pathways.
- Restoration of neural pathways damaged by ALS and other neurological disorders.